SCHEMBL10050841

SCHEMBL10050841

CC(C)(C)C1NCCN1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19823633 0.87
SCHEMBL18179866 0.87
SCHEMBL23356550 0.84 ALDH1A1 (0.30)
SCHEMBL19640960 0.71
SCHEMBL12641396 0.71
SCHEMBL16998936 0.69 TSHR (0.30)
SCHEMBL19733927 0.65
SCHEMBL3916864 0.64
SCHEMBL18886268 0.63
Hydrochloric Acid SCHEMBL28001389 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12043623-B2 Purinones as ubiquitin-specific protease 1 inhibitors FORMA THERAPEUTICS, INC. (US) 2024-07-23 US disclosed
CN-114933613-B Preparation of PNNP ligand, ethylene oligomerization catalyst and application thereof 万华化学集团股份有限公司 2024-02-27 CN disclosed
US-20230355599-A1 BIOMARKERS FOR CBL, AND COMPOSITIONS AND METHODS FOR THEIR USE NURIX THERAPEUTICS, INC. 2023-11-09 US disclosed
US-20230355599-A1 BIOMARKERS FOR CBL, AND COMPOSITIONS AND METHODS FOR THEIR USE NURIX THERAPEUTICS, INC. 2023-11-09 US disclosed
CN-114920866-B Preparation method of polyolefin thermoplastic elastomer 万华化学集团股份有限公司 2023-07-14 CN disclosed
US-20230212186-A1 CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF NURIX THERAPEUTICS, INC. 2023-07-06 US disclosed
US-20230150991-A1 SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF NURIX THERAPEUTICS, INC. 2023-05-18 US disclosed
US-20230037255-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS INFLAZOME LTD (IE) 2023-02-02 US disclosed
CN-114933613-A Preparation of PNNP ligand, ethylene oligomerization catalyst and application thereof 万华化学集团股份有限公司 2022-08-23 CN disclosed
CN-114920866-A Preparation method of polyolefin thermoplastic elastomer 万华化学集团股份有限公司 2022-08-19 CN disclosed
US-20200291003-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS SYGNATURE DISCOVERY LIMITED (GB) 2020-09-17 US disclosed
US-20200247812-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE INTEGRAL BIOSCIENCES PRIVATE LTD (IN) 2020-08-06 US disclosed
US-10399980-B2 Purinones as ubiquitin-specific protease 1 inhibitors FORMA THERAPEUTICS, INC. (US) 2019-09-03 US disclosed
US-20190134056-A1 K-RAS MUTATIONS AND ANTAGONISTS THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOG (US) 2019-05-09 US disclosed
US-10189841-B2 Purinones as ubiquitin-specific protease 1 inhibitors FORMA THERAPEUTICS, INC. (US) 2019-01-29 US disclosed
US-20170145012-A1 PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS FORMA THERAPEUTICS, INC. 2017-05-25 US disclosed
US-9592186-B2 Topical compositions and methods for skin lightening AVON PRODUCTS, INC. (US) 2017-03-14 US disclosed
US-9566224-B2 Tyrosinase inhibitors AVON PRODUCTS, INC. (US) 2017-02-14 US disclosed
US-8168212-B2 Topical compositions comprising non-proteogenic amino acids and methods of treating skin AVON PRODUCTS, INC (US) 2012-05-01 US disclosed
US-20100261769-A1 Topical Compositions Comprising Non-Proteogenic Amino Acids and Methods of Treating Skin AVON PRODUCTS, INC. (US) 2010-10-14 US disclosed